ARV7 test

[Anonymous]

When will the ARV7 biomarker test be available commercially? What company will be producing it? Little response to Xtandi or Zytiga if patient tests positive for ARV7. I'm sure the payers will pay for a test to show which metastatic prostate patients get no response to these expensive orals...

 

[Anonymous]

According to data held by Medivation as well as Astellas, 30-35% of patients with mCRPC will not respond to Enzalutamide. Unfortunately for Medivation/Astellas if the testis used, companies will lose 1/3 of patients.
This is all about sale. Business side of company argues that even those patients receive about 3 month of therapy that will translate to so much money.
Pharma, especially Astellas and Medivation do NOT care much about patients care and money that they have to spend via co-pay. In some books, they are called thieves.

 

[Anonymous]

According to data held by Medivation as well as Astellas, 30-35% of patients with mCRPC will not respond to Enzalutamide. Unfortunately for Medivation/Astellas if the testis used, companies will lose 1/3 of patients.
This is all about sale. Business side of company argues that even those patients receive about 3 month of therapy that will translate to so much money.
Pharma, especially Astellas and Medivation do NOT care much about patients care and money that they have to spend via co-pay. In some books, they are called thieves.

That is why a commercialized biomarker for ARV7 is so very important…why have a 1/3 of patients waste their money and survival time on a drug that won't work for them. I'm sure it won't take long for some diagnostic company to seize the opportunity to develop the test….

 

[Anonymous]

You are correct but Medivation and Astellas will do everything in their power, even withholding data or denying data not to allow such diagnostic test to be developed.
They are thieves and they don't care about patients or their financial issues.

 

[Anonymous]

You are correct but Medivation and Astellas will do everything in their power, even withholding data or denying data not to allow such diagnostic test to be developed.
They are thieves and they don't care about patients or their financial issues.

Than the lawyers of these patients who get an expensive drug that does nothing for them will sue both companies and win.

 

[Anonymous]

well the ARV7 data is all out in the New England Journal of Medicine (9/11/14) and its not going to help our sales one bit…if Astellas was smart they would help develop this diagnostic test with John Hopkins instead of Genoptix.

 

[Anonymous]

That is why a commercialized biomarker for ARV7 is so very important…why have a 1/3 of patients waste their money and survival time on a drug that won't work for them. I'm sure it won't take long for some diagnostic company to seize the opportunity to develop the test….

Marketing trolls for comp love to drop bait lines here on CP. Lazy, yes, but makes their job sooooo much easier. Gotta pay for that dumbed down PhD degree some how.

 

[Anonymous]

Marketing trolls for comp love to drop bait lines here on CP. Lazy, yes, but makes their job sooooo much easier. Gotta pay for that dumbed down PhD degree some how.

Let's see...Abbie goes generic, astellas has no pipeline, and when ARV7 bio marker goes generic.... I guess you will be calling a headhunter to find another opportunity...all of the above will be on u sooner than u think!

 

[Anonymous]

Let's see...Abbie goes generic, astellas has no pipeline, and when ARV7 bio marker goes generic.... I guess you will be calling a headhunter to find another opportunity...all of the above will be on u sooner than u think!

Ummmm, guess you just confirmed you're a CI troll. Also confirmed you're an arrogant SOB. Oh and head hunters are often useless con artist.

 

[Anonymous]

Let's see...Abbie goes generic, astellas has no pipeline, and when ARV7 bio marker goes generic.... I guess you will be calling a headhunter to find another opportunity...all of the above will be on u sooner than u think!

you mean when the ARV7 biomarker becomes commercialized by John Hopkins and whatever company steps up to the plate…Astellas should go for it before J & J partners with Hopkins.